

PATENT Docket No. 1400-004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	, )
	) Group Art Unit: 1616
William J. Roberts	)
	) Examiner: Qazi, Sabiha Naim
Entitled: "BIOAVAILABLE PRODRUGS OF	)
ANDROGENIC STEROIDS AND RELATED	)
METHOD"	)
	ý)
Serial No.: 10/053,505	, )
20.000,000	, )
Filed: January 16, 2002	, )
	, )
•	,

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Applicant hereby submits this Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97(c) to bring to the attention of the Examiner the document listed on the attached Form PTO/SB/08B. It is being filed after the occurrence of events identified in § 1.97(b), but upon information and belief before the mailing date of either a final office action or a notice of allowance. A copy of the listed document is attached.

Applicant also brings to the attention of the Examiner a co-pending application, Application Serial No. 10/123,068 (Attorney Docket No. 1400-059). A copy of the application is enclosed.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that the listed document is ADDF01 - 00000014 10053505

180.00 OP

02 FC:1806

material or constitutes "prior art." Applicant reserves the right to challenge the characterization of the document or information as "prior art." Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed document, should the document be applied against the claims of the present application.

Consideration of the foregoing and enclosures plus return of a copy of the attached Form PTO/SB/08B with the Examiner's initials in the left column per MPEP 609 are earnestly solicited.

A check for \$180.00 is enclosed to cover the fee set forth in 37 C.F.R. § 1.17(p) required by 37 C.F.R. § 1.97(c) in lieu of certification. If this is deficient or if there are any other fees due in connection with this application, please charge the deficiency to our Deposit Account No. 501324.

Dated: November 4, 2003

Respectfully submitted,

hIMalcoh

Sarah L. Malcolm Reg. No. 53,259

## **CERTIFICATE OF EXPRESS MAILING**

Express Mail Label No. EV 260562255 US

Date of Deposit: November 4, 2003

I hereby certify that this Information Disclosure Statement with attached Form PTO/SB/08B, copy of listed documents, Fee Transmittal for FY 2004 (2 copies) and check are being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SarahSMalcoli

3

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

erwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

A Strostitute for form 1449/PTO				Complete if Known		
AABIUSIIIUII	e 10/10/11/ 1449/F10			Application Number	10/053,505	
INFORMATION DISCLOSURE			CLOSURE	Filing Date	January 16, 2002	· · · - · · ·
STATEMENT BY APPLICANT		First Named Inv ntor	William J. Roberts	<del> </del>		
	(llas as many she	asta aa m		Art Unit	1616	
(Use as many sheets as necessary)		Examiner Name	Qazi, Sabiha Naim			
Sheet	1	of	1	Attorney Docket Number	1400-004	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>		
		MARWAH, P. et al., "Ergosteroids IV: Synthesis and Biological Activity of Steroid Glucuronosides, Ethers, and Alkylcarbonates," Steroids, 2001, pp. 581-595, vol. 66, Elsevier.			
· · · · · · · · · · · · · · · · · · ·					

	·		
Examiner		Date .	
Signature		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.